Anesthesiologists are responsible for making transfusion decisions for surgical patients on a routine basis. They must weigh benefits versus known and emerging risks of transfusion. As the risks of viral transmission by transfusion have declined, noninfectious complications of transfusion have become the most important blood safety issues. Reports from the Food and Drug Administration (FDA) and various hemovigilance networks indicate that transfusion-related acute lung injury (TRALI) has emerged as the leading cause of transfusion-related morbidity and mortality.1 Although initially described decades ago, recent agreement on diagnostic criteria has provided practical clinical definitions of TRALI to aid the clinician in diagnosis and to facilitate its study. Advances in the understanding of the pathogenesis of TRALI have led to new strategies aimed at reducing the risk of this complication.
Definition of TRALI
The link between symptoms of acute lung injury (ALI), transfusion and leukoagglutinins was first reported by Brittingham in 1957.2 It was not until the early 1980s that Popovsky et al. coined the term “transfusion-related acute lung injury” and described the first series of cases and the relationship to leukoagglutinins in the blood component.3,4 Increasing awareness of the significance of TRALI in blood safety led the National Heart, Lung, and Blood Institute (NHLBI) to convene a working group of experts to identify research needs and provide a clinically useful definition. The group defined TRALI as “new acute lung injury (ALI) occurring during or within 6 h after a transfusion, with a clear temporal relationship to transfusion, in patients without or with risk factors for ALI other than transfusion.”5 Limitations to the proposed NHLBI working group definition are the exclusion of patients with preexisting ALI, excluding cases with onset more than 6 h after transfusion, lack of laboratory diagnostic criteria and a required severity of hypoxia that could miss subtle cases of TRALI. A subsequent Canadian Consensus conference in April 2004 further modified the NHLBI working group criteria for TRALI (Table 1).1,6 The modified criteria broadened the definition of hypoxia to include clinical evidence of hypoxia and created a category of “possible TRALI” to address cases in which patients have other risk factors for ALI such as sepsis, aspiration, near-drowning, disseminated intravascular coagulation, trauma, pneumonia, drug overdose, fracture, burns and cardiopulmonary bypass.1 It was acknowledged that subtle cases may not meet the Canadian Consensus definition, nor was there agreement on how to diagnose subtle cases. However, these criteria would allow for the great majority of clinically significant cases to be captured.
Clinical and Laboratory Features
TRALI has a clinical presentation mirroring acute respiratory distress syndrome occurring in the setting of transfusion. Patients present with respiratory distress (dyspnea), hypoxia, pulmonary edema on examination, and bilateral fluffy infiltrates on chest radiograph during or within 6 h of transfusion. The majority of cases occur during or within 1 to 2 h of transfusion.4 Signs and symptoms include tachypnea, frothy pulmonary secretions, hypotension (less commonly hypertension), fever, tachycardia and cyanosis. Auscultation of the lung fields reveals diffuse rales. The leaky capillary endothelium results in tracheal fluid that is characteristically exudative. Importantly, there is no evidence of circulatory overload with absence of jugular venous distension or a S3 gallop. Central venous pressure and pulmonary capillary wedge pressure is normal. B-natriuretic peptide may have some value in distinguishing transfusion-associated circulatory overload (TACO) from TRALI.7 TACO is suggested by an absolute B-natriuretic peptide level more than 100 pg/dl and a posttransfusion to pretransfusion ratio more than 1.5.7 Laboratory findings in the acute setting are of limited value because they are only suggestive and not diagnostic of TRALI. Such findings include leucopenia, neutropenia, monocytopenia and hypocomplementemia.1,8 Laboratory tests which strongly support, but are not required for the clinical diagnosis of TRALI, include the demonstration of human leukocyte antigen (HLA) class I or class II or neutrophil-specific antibodies in donor plasma and the presence of the cognate (corresponding) antigen on recipient neutrophils (see section on Antibody-Mediated TRALI). Such testing typically takes days or weeks to perform and is not helpful clinically. Tests for lipid priming activity or neutrophil-activating factors in the plasma from the blood component are only available on a research basis.
The diagnosis of TRALI is based on clinical criteria derived from the NHLBI working group and Canadian Consensus conference guidelines. In practice it can be difficult to differentiate TRALI from TACO9 and it is possible that there may be both complications concurrently in a patient. One cannot make a diagnosis of TRALI with current criteria if a patient has ALI before the suspected transfusion. A diagnosis of possible TRALI can be made if there are preexisting risk factors for ALI other than transfusion. Undoubtedly, as experience in recognition and understanding of TRALI grows, the criteria will evolve with improved sensitivity and specificity for TRALI.
Management of TRALI
Treatment of TRALI is primarily supportive with supplemental oxygen and in most cases ventilatory support. In contrast to acute respiratory distress syndrome from other causes, patients typically recover quickly, with resolution of pulmonary infiltrates within 96 h of the transfusion. The mortality rate has been reported to be between 5% and 10%.10 Patients with TRALI are euvolemic or may be hypovolemic as a result of excessive fluid leakage into the lung. Whereas rapid volume reduction with diuresis is the treatment of choice for TACO,9 in patients with TRALI, diuretics may cause hypovolemia.11 There are no data regarding the efficacy of steroids, so their role remains unclear.
Incidence and Implicated Blood Components
TRALI has clearly emerged as the leading cause of transfusion-related mortality representing the leading cause of transfusion-related death reported to the FDA since 2003.12 In 2006, the most recent year of data, there were 35 reported deaths due to TRALI, more than all other causes of transfusion-related mortality combined.13 The true incidence of TRALI is unknown because a standardized definition has only recently been developed. Initial studies quoted a per component incidence of 1:5000 blood components4 with subsequent reports ranging from 1:432 whole blood platelets to 1:557,000 red cells.1 TRALI has been reported from all types of blood components including whole blood, red cells, apheresis platelets, whole blood platelets, fresh frozen plasma, cryoprecipitate, granulocytes, stem cell products and even IV immunoglobulin preparations.14 Most implicated blood products contain more than 50 mL of plasma.1 A recent report of a passive TRALI surveillance system in the American Red Cross from 2003 to 2005 used the Canadian Consensus conference as the primary diagnostic criteria.15 They reported a per component risk of fatality from probable TRALI as shown in Fig. 1. Fresh frozen plasma has also been implicated most frequently in TRALI cases and TRALI-related deaths reported to the FDA12 and United Kingdom.16 The only prospective cohort clinical surveillance study to use current diagnostic guidelines for TRALI reported an 8% incidence of TRALI in their intensive care unit population and that plasma and platelet transfusions were associated with greatest risk of TRALI.17 These data suggest that passive reporting systems greatly under-estimate the number of TRALI cases. However, both passive and prospective surveillance studies using current criteria for TRALI diagnosis suggest that the plasma-rich components, such as plasma and apheresis platelets have the highest per component risk.
Pathophysiology of TRALI
The exact mechanism of TRALI is not fully understood. An immune antibody-mediated mechanism has been implicated in most cases of TRALI. In a minority of reported cases, however, an antibody was not identified and an alternative “two hit” immune mechanism has been postulated. Data from animal models of TRALI and more recent clinical data have suggested that both mechanisms occur and that TRALI may represent the final common pathway of neutrophil priming, activation, endothelial injury and capillary leak, which can be triggered by antibodies and/or other biologic response modifiers in patients with or without underlying risk factors. The pathogenesis of TRALI has been recently elegantly reviewed by Bux and Sachs18,19 (Fig. 2).
The antibody-mediated mechanism postulates that passive transfer of leukoagglutinating antibodies via transfusion of plasma containing blood components results in binding to recipient neutrophils. Antibody-bound neutrophils are activated and sequestered in the lungs where complement activation and release of neutrophil bioactive products results in endothelial damage, capillary leak and ALI. In 65% to 90% of reported clinical cases of TRALI, leukocyte antibodies have been identified in the implicated donor.4,16,20–22 The corresponding (cognate) antigen can be identified on neutrophils of the recipient in most of these cases.4,22 Antibodies which have been implicated in TRALI include donor HLA class I, HLA class II, and/or neutrophil-specific antibodies.1,4,20–24 In the prospective surveillance study by Gajic et al., the odds ratio for TRALI was increased in recipients of blood units that contained HLA class II and neutrophil antibodies and a trend for those containing HLA class I antibodies.17 Although a number of neutrophil-specific antibodies have been reported, the most common is directed at the 5b (HNA-3a) antigen.10,25 In a small percent of cases, the leukoagglutinating antibody appears to be from the recipient and is directed at the transfused neutrophils.26–28 Most of the donors implicated in TRALI have been multiparous women who became alloimmunized during pregnancy. The frequency of sensitization to HLA class I and class II antigens has been recently studied in more than 5000 United States (US) female blood donors using sensitive flow cytometry-based multi-antigen Luminex testing. The prevalence of HLA class I and class II antibodies is highly correlated with parity, with alloimmunization rates in women with zero, 1,2,3 or more pregnancies of 1.7%, 11.2%, 22.3%, and 29.8%, respectively.29 Alloimmunization to neutrophil-specific antigens is much less frequent 0.1−1.8%.30,31 HLA class II antigens are also expressed on monocytes and may contribute to TRALI.23
The antibody-mediated model is supported by both animal models and clinical data. Seeger et al.32 developed a rabbit ex vivo lung model for TRALI. Lung injury was observed when isolated lungs were perfused with human HNA-3a(5b) positive neutrophils followed by anti-5b and a source of complement, but not in the absence of anti-5b, use of 5b negative neutrophils or with control rabbit plasma. Similar results were found in a recent in vivo mouse model which demonstrated ALI and increased mortality when a monoclonal MHC-I antibody was infused into mice with the cognate antigen.33 The lung injury was dependent on neutrophil expression of Fcγ receptors and was prevented in mice depleted of neutrophils with anti-granulocyte antibodies. A recently published ex vivo rat lung model found that lung injury occurred in rats perfused with human HNA-2a positive neutrophils followed by administration of a mouse monoclonal neutrophil antibody with HNA-2a (CD-177) specificity independent of the presence of complement.34 When neutrophils with <30% expression of anti–HNA-2a were used, the injury was greatly attenuated. Anti–HNA-2a was able to mediate lung damage without endotoxin activation of the lungs when high HNA-2a expressing neutrophils were used but endotoxin costimulation greatly accelerated lung vascular permeability.34 An in vitro model by Silliman et al.35 using human pulmonary microvascular endothelial cells (HMVECs) and human HNA-3a antibodies found that these antibodies caused HNA-3a positive neutrophils to become primed and elicit a respiratory burst. However, they only mediated the damage of the HMVECs if there was previous activation of the HMVECs with endotoxin. This study implies that there must be some endothelial activation for leukocyte antibodies to mediate endothelial damage. The necessity of pulmonary endothelial activation for antibody-mediated TRALI remains controversial. Differences in the models of Sachs and Silliman et al. include human versus mouse anti-neutrophil antibodies, different neutrophil antibody specificity and HMVEC culture versus ex vivo rat lungs as target endothelial cells. Sachs postulated that recipient neutrophils require a threshold stimulation that can be accomplished by antibody alone in some circumstances, but is facilitated by previously activated endothelium.19 The development of TRALI in healthy volunteers supports this theory.36
A large body of circumstantial clinical evidence links TRALI to leukocyte antibodies by virtue of their presence in the large majority of reported cases. Other supportive clinical data include a prospective, randomized, crossover study of 2 U of plasma from multiparous donors (≥3 live births) versus control plasma in 105 intensive care patients.37 This study found that patients who received study plasma had impaired lung function as evidenced by a decrease in Pao2:Fio2 ratio versus controls. As previously noted, a prospective surveillance study by Gajic et al. reported that recipients of units with leukocyte antibodies had a higher risk of developing TRALI.17 Dykes et al.38 reported TRALI in a single-lung transplant recipient after a red cell transfusion containing HLA-B44 antibodies. Lung injury was found only in the B44 positive transplanted lung but not in the B44 negative native lung. The impact of switching to male plasma in the UK was recently reported in a before and after study of 211 patients who underwent repair of a ruptured abdominal aortic aneurysm. They found a reduction in the incidence of ALI within 6 h of surgery from 36% to 21% (P = 0.04) and fewer patients were hypoxic (87% vs 62%, P < 0.01).39 Thus clinical data and animal data support a leukocyte antibody-mediated mechanism for TRALI.
“Two Hit” Mechanism for TRALI
Despite the strong experimental and clinical evidence supporting an antibody mechanism of TRALI, there are inconsistencies. First, antibodies have not been found in 15% or more of cases of TRALI.10 The use of more sensitive assays for HLA or neutrophil antibodies or identification of antibodies to other cell types, such as monocytes21 or lymphocytes,22 may explain some of these cases. Second, although HLA antibodies are commonly found in female donors, only a very small proportion of these donors are implicated in TRALI. Third, donors with known HLA antibodies transfused to patients with the cognate antigen caused lung injury in some patients but not others.40,41 Fourth, patients who have experienced TRALI reactions do not always have the cognate antigen to leukocyte antibodies found in the implicated donor.21 An antibody-independent mechanism for TRALI has been proposed to explain these discrepancies. A two hit model has been proposed by Silliman et al.35,42,43 which postulates that an initial insult to vascular endothelium results in endothelial activation, release of cytokines and expression of adhesion molecules. Cytokines attract and prime neutrophils which firmly adhere to the endothelium. Events which could cause the initial proinflammatory endothelial activation include severe infection, surgery, trauma or massive transfusion. A second hit activates sequestered adherent neutrophils to release oxidases and proteases which damage the endothelium causing capillary leak and ALI. The second hit may be mediated by transfusion of biologic response modifiers, such as leukocyte antibodies, lipid priming molecules,44,45 cytokines, CD40 ligand46 or endotoxin.34,35 Animal studies have provided support for this hypothesis. An ex vivo rat model demonstrated ALI when rats were infused with endotoxin (first hit) and then followed with plasma from stored, but not fresh, platelets45 or red cells.44 Silliman et al. showed that infusion of lipids (lysophosphatidylcholines) extracted from the plasma supernatant of stored, but not fresh, platelets also caused ALI, demonstrating lipid priming activity as an important causative agent in stored blood components. The recent studies, mentioned above, by Sachs et al.,34 using an ex vivo rat model and Silliman et al., using HMVECs in vitro35 further support the two hit hypothesis. Clinical studies also provide support for a nonimmune mechanism. A nested case-controlled study of 46 TRALI cases due to whole blood platelet concentrates found the same incidence of leukocyte antibodies in control donor components versus those implicated in TRALI.47 Furthermore, components implicated in TRALI had greater plasma-priming activity compared with components not implicated in TRALI. A smaller retrospective study of 10 consecutive patients with TRALI found HLA or granulocyte antibodies in donors in only 50% of cases and a predisposing event in all 10 patients.48 In this study, greater lipid priming activity was found in the plasma of patients with TRALI compared with controls or the patient’s pretransfusion samples. One limitation of the two hit model is the appearance of TRALI in patients who were apparently healthy before transfusion, such as in the setting of coumadin reversal for elective surgery.36,41 It is possible that such patients have subclinical evidence, or unrecognized risk factors for endothelial activation. Alternatively, a transfused component may contain a sufficiently strong antibody or provide both the mediators of endothelial activation and the second hit bioactive molecules which activate neutrophils and trigger TRALI.
Prevention of TRALI
Recent advances in the understanding of TRALI have led to new risk reduction measures. Until recently, the primary measure to prevent TRALI has been the deferral of donors implicated in a TRALI case. The AABB 24th edition of Standards for Blood Banks and Transfusion Services requires that donors implicated in a TRALI case be evaluated for eligibility to donate.49 There is no consensus regarding donor investigation or management of donors implicated in a TRALI case. Blood centers typically consider the likelihood that a case is bona fide TRALI, the number and types of donors involved and antibody specificity.50 Multiparous female donors are considered to be the highest risk donors. Donors found to have leukocyte antibodies corresponding to an antigen on the patient leukocytes or exhibiting a positive crossmatch between donor serum and patient leukocytes are deferred indefinitely or at least from donating plasma containing blood components.
Component factors have also been considered to reduce the risk of TRALI. The use of fresher platelets or red cells with reduced lipid priming activity1 or washed components has also been considered but is not currently recommended. A strategy that has been widely adopted is to use plasma exclusively or primarily from male donors and divert plasma from female donors to recovered plasma, which is only used for fractionation and production of plasma derivatives. The UK adopted this strategy in October 2003 with full implementation in January 2004. The UK Serious Hazards of Transfusion data showed that TRALI cases associated with plasma-rich components decreased from 16 cases in 2003 to 3 cases in 2005.51 Other countries in Europe use pooled solvent detergent plasma, which has never been associated with a case of TRALI.52 American Red Cross surveillance data from 2003 to 2005 showed that 71% of the 38 reported probable TRALI-related fatalities and 75% (18/24) of the cases from plasma were from antibody-positive female donors.15 These data suggested that diversion of female plasma could substantially reduce the number of TRALI cases. Prompted by these data the AABB issued a bulletin on November 3, 2006 outlining recommendations to reduce the risk of TRALI which included minimizing preparation of plasma-rich components from high risk donors.53 Importantly, it identified that appropriate use of plasma is an important component of TRALI risk reduction. This bulletin resulted in the widespread use of male donors as the primary source for plasma units in the US. Apheresis platelets contain a similar amount of plasma to plasma units; however, a similar strategy for platelets would be very difficult to implement due to supply limitations if female apheresis donors were not used. An alternative strategy would be to divert only those apheresis donors with a history of pregnancy or transfusion or to test female donors for leukocyte antibodies. An NHLBI funded Leukocyte Antibody Prevalence Study was recently completed by the REDSII research network.29,54 The study showed that transfusion had a minimal impact on HLA alloimmunization and that women who did not report a history of pregnancy had a prevalence of HLA antibodies similar to men. Among women who reported a history of pregnancy, 24% had class I and/or class II HLA antibodies. Diverting such donors from apheresis platelet donation was estimated to result in the loss of approximately 6% of apheresis platelet components. It is feasible that such a loss could be replaced with additional donors or use of whole blood platelets. Lastly, removal of plasma from platelet components and replacement with platelet additive solutions may be another practical way to reduce the plasma content and risk of TRALI from platelets. Platelet additive solutions are not currently licensed in the US but are expected to be soon.
TRALI has emerged as the leading cause of transfusion-related morbidity and mortality in the US. TRALI is a clinical diagnosis and is difficult to distinguish from TACO. Recently developed consensus clinical definitions will help provide consistency in identifying TRALI cases, facilitate establishing the true incidence of TRALI, and provide a framework from which laboratory and clinical studies can be performed. Such data will contribute to the development of novel strategies for treatment and additional measures to reduce the risk of TRALI.
1.Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA. Proceedings of a consensus conference: towards and understanding of TRALI. Transfus Med Rev 2005;19:2–31
2.Brittingham TE. Immunologic studies on leukocytes. Vox Sang 1957;2:242–8
3.Popovsky MA, Abel MD, Moore SB. Transfusion related acute lung injury associated with passive transfer of antileukocyte antibodies. Am Rev Respir Dis 1983;128:185–9
4.Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 1985;25:573–7
5.Toy P, Popovsky MA, Abraham E, Ambruso DR, Holness LG, Kopko PM, McFarland JG, Nathens AB, Silliman CS, Stroncek D. The National Heart Lung and Blood Institute Working Group on TRALI. Transfusion-related acute lung injury: definition and review. Crit Care Med 2005;33:721–6
6.Kleinman S, Caufield T, Chan P, Davenport R, McFarland J, McPhedran S, Meade M, Morrison D, Pinsent T, Robillard P, Slinger P. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion 2004;44:1774–89
7.Zhou L, Giacherio D, Cooling L, Davenport RD. Use of B-natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion-associated circulatory overload. Transfusion 2005;45:1056–63
8.Nakagawa M, Toy P. Acute and transient decrease in neutrophil count in transfusion-related acute lung injury: cases at one hospital. Transfusion 2004;44:1689–94
9.Gajic O, Gropper MA, Hubmayr RD. Pulmonary edema after transfusion: how to differentiate transfusion associated circulatory overload from transfusion related acute lung injury. Crit Care Med 2006;34(suppl):S109–13
10.Webert KE, Blajchman MA. Transfusion-related acute lung injury. Curr Opin Hematol 2005;12:480–7
11.Wallis JP. Transfusion-related acute lung injury (TRALI): presentation, epidemiology and treatment. Intensive Care Med 2007;33(suppl 1):S12–16
12.Holness L, Knippen MA, Simmons L, Lachenbruch PA. Fatalities caused by TRALI. Transfus Med Rev 2004;18:184–8
13.Fatalities reported to the FDA following blood collection and transfusion. In: Proceedings of the Annual Summary for Fiscal Years 2005 and 2006. Available at http://www.fda.gov/CBER/blood/fatal0506.htm
. Accessed March 3, 2008
14.Rizk A, Gorson KC, Kenney L, Weinstein R. Transfusion-related acute lung injury after the infusion of IVIG. Transfusion 2001;41:264–8
15.Eder AF, Herron R, Strupp A, Edward BD, Notari EP, Chambers LA, Dodd RY, Benjamin RJ. Transfusion related acute lung injury surveillance (2003–2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion 2007;47:599–607
16.Serious Hazards of Transfusion, 2004 Annual Report. Available at: http:www.shot-uk.org
17.Gajic O, Rana R, Winters J, Yilmaz M, Mendez JL, Rickman OB, O’Byrne MM, Evenson LK, Malinchoc M, DeGoey SR, Afessa B, Hubmayr RD, Moore SB. Transfusion-related acute lung injury in the critically ill: prospective nested case control study. Am J Respir Crit Care Med 2007;176:886–91
18.Bux J, Sachs UJ. The pathogenesis of transfusion related acute lung injury (TRALI). Br J Haematol 2007;136:788–99
19.Sachs UJ. Pathophysiology of TRALI: current concepts. Intensive Care Med 2007;33(suppl 1):S3–11
20.Popovsky MA, Haley NR. Further characterization of transfusion-related acute lung injury: demographics: clinical and laboratory features, and morbidity. Immunohematology 2000;16:157–9
21.Kopko PM, Paglieroni TG, Popovsky MA, Muto KN, MacKenzie MR, Holland PV. TRALI: correlation of antigen-antibody and monocyte activation in donor recipient pairs. Transfusion 2003;43:177–84
22.Wallis JP, Lubenko A, Wells AW, Chapman CE. Single hospital experience of TRALI. Transfusion 2003;43:1053–9
23.Kopko PM, Popovsky MA, MacKenzie MR, Paglieroni TG, Muto KN, Holland PV. HLA class II antibodies in transfusion-related acute lung injury. Transfusion 2001;41:1244–8
24.Kao GS, Wood IG, Dorfman DM, Milford EL, Benjamin RJ. Investigations into the role of anti-HLA class II antibodies in TRALI. Transfusion 2003;43:185–91
25.Davoren A, Curtis BR, Shulman IA, Mohrbacher AF, Bux J, Kwiatkowska BJ, MacFarland JG, Aster RH. TRALI due to granulocyte-agglutinating human neutrophil antigen-3a (5b) alloantibodies in donor plasma: a report of 2 fatalities. Transfusion 2003;43:641–5
26.Englelfriet CP, Reesink HW, Brand A, Palfi M, Popovsky MA, Martin-Vega C, Ribera A, Rouger P, Goldman M, Decary F, Freedman J, Lucas G, Navarette C, Neppert J, Lin M, Zupanska B. Transfusion-related acute lung injury (TRALI). Vox Sang 2001;81:269–83
27.Bux J, Becker F, Seeger W, Kilpatrick D, Chapman J, Waters A. Transfusion-related acute lung injury due to HLA-A2-specific antibodies in recipient and NB-1 specific antibodies in donor blood. Br J Haematol 1996;93:707–13
28.Sachs UJ, Bux J. TRALI after the transfusion of cross-match-positive granulocytes. Transfusion 2003;43:1683–6
29.Triulzi D, Kakaiya R, Kleiman S, Busch M, Norris P, Steele W, Hillyer CD, Schreiber G. Relationship of HLA antibodies in blood donors to pregnancy and transfusion history. Transfusion 2007;47(suppl 2):2A
30.MacLennan S, Lucas G, Brown C, Evans R, Kallon D, Brough S, Contreras M, Navarrete C. Prevalence of HLA and HNA antibodies in donors: correlation with pregnancy and transfusion history. Vox Sang 2004;87(suppl 3):S2–16
31.Clay M, Kline W, McCullough J. The frequency of granulocyte specific antibodies in postpartum sera and a family study of the 6B antigen. Transfusion 1984;24:252–5
32.Seeger W, Schneider U, Kreusler B, Witzleben EV, Walmrath D, Grimminger F, Neppert J. Reproduction of transfusion—related acute lung injury in an ex vivo lung model. Blood 1990; 76:1438–44
33.Looney MR, Su X, Van Ziffle JA, Lowell CA, Matthay MA. Neutrophils and their Fcγ receptors are essential in a mouse model of transfusion-related acute lung injury. J Clin Invest 2006;116:1615–23
34.Sachs UJ, Hattar K, Weissmann N, Bohle RM, Siblelius U, Bux J. Antibody-induced neutrophil activation as a trigger for transfusion-related acute lung injury. Blood 2006;107:1217–19
35.Silliman CC, Curtis BR, Kopko PM, Khan SY, Kelher MR, Schuller RM, Sannoh B, Ambruso DR. Donor antibodies to HNA-3a implicated in TRALI reactions prime neutrophils and cause PMN-mediated damage to human pulmonary microvascular endothelial cells in a two-event in vitro model. Blood 2007;109:1752–5
36.Dooren MC, Ouwehand WH, Verhoeven AJ, von dem Borne AE, Kuijpers RW. Adult respiratory distress syndrome after experimental intravenous gamma-globulin concentrates and monocyte-reactive IgG antibodies. Lancet 1998;352:1601–2
37.Palfi M, Berg S, Ernerudh J, Berlin G. A randomized controlled trial of transfusion-related acute lung injury: is plasma from multiparous blood donors dangerous? Transfusion 2001;41: 317–22
38.Dykes A, Smallwood D, Kotsimbos T, Treet A. Transfusion related acute lung injury (TRALI) in a patient with a single lung transplant. Br J Haematol 2000;109:674–6
39.Wright SE, Snowden CP, Athey SC, Leaver AA, Clarkson JM, Chapman CE, Roberts DRD, Wallis JP. Acute lung injury after abdominal aortic aneurysm repair: the effect of excluding donations from females from the production of fresh frozen plasma. Crit Care Med 2008;36:1796–802
40.Toy P, Hollis-Perry KM, Jun J, Nakagawa M. Recipients of blood from a donor with multiple HLA antibodies: a lookback study of transfusion-related acute lung injury. Transfusion 2004;44: 1683–8
41.Kopko PM, Marshall CS, Mackenzie MR, Holland PV, Popovsky MA. Transfusion-related acute lung injury: report of a clinical look-back investigation. JAMA 2002;287:1968–71
42.Silliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. Blood 2005;105:2266–73
43.Silliman CC, Kelher M. The role of endothelial activation in the pathogenesis of transfusion-related acute lung injury. Transfusion 2005;45(suppl):S109–16
44.Silliman CC, Voelkel NF, Allard JD, Elzi DJ, Tuder RM, Johnson JL, Ambruso DR. Plasma and lipids from stored red cells cause acute lung injury in an animal model. J Clin Invest 1998; 101:1458–67
45.Silliman CC, Bjornsen AJ, Wyman TH, Kelher M, Allard J, Bieber S, Voelkel NF. Plasma and lipids from stored platelets cause acute lung injury in an animal model. Transfusion 2003; 43:633–40
46.Khan SY, Kelher MR, Heal JM, Blumberg N, Boshkov LK, Phipps R, Gettings KF, McLaughlin NJ, Silliman CC. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a cofactor in the development of transfusion-related acute lung injury. Blood 2006;108:2455–62
47.Silliman CC, Boshkov LK, Mehdizadehkashi Z, Elzi DJ, Dickey WO, Podlosky L, Ckarke G, Ambruso DR. Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood 2003;101:454–62
48.Silliman CC, Paterson AJ, Dickey WO, Stroncek DF, Popovsky MA, Caldwell SA, Ambruso DR. The association of biologically active lipids with the development of transfusion-related acute lung injury: a retrospective study. Transfusion 1997;37:719–26
49.AABB Standards for blood banks and transfusion services. 24th ed. Bethesda, MD: AABB Press, 2006
50.Su L, Kamel H. How do we investigate and manage donors associated with a suspected case of transfusion-related acute lung injury. Transfusion 2007;47:1118–24
51.Chapman CE, Williamson LM, Cohen H, Stainsby D, Jones H. The impact of using male donor plasma on haemovigilance reports of transfusion associated acute lung injury (TRALI) in the UK (abstract). Vox Sang 2006;91(suppl 3):227
52.Sachs UJH, Kauschat D, Bein G. White blood cell-reactive antibodies are undetectable in solvent/detergent plasma. Transfusion 2005;45:1628–31
53.AABB Association Bulletin 06–07. Transfusion-related acute lung injury, 2006. Available at http://www.aabb.org
54.Triulzi D, Kakaiya R, Schreiber G. Donor risk factors for white blood cell antibodies associated with transfusion related acute lung injury: REDS II Leukocyte Antibody Prevalence Study (LAPS). Transfusion 2007;47:563–4